China’s biopharma sector enters the New Year on a high
A wave of lucrative licensing deals, drug approvals and positive policy moves spurred a pharmaceutical rally in 2025, but bigger biotechs are seeing more of the benefits Key Takeaways: The…
PW Medtech’s Buying Spree: Diversification or Insider Story?
The manufacturer of medical infusion devices has recently made two interesting acquisitions Key takeaways: After buying a related peer in November, PW Medtech acquired a human tissue regeneration and repair…
RELATED ARTICLES
-
WORK Medical enters strategic partnerships in bid to explore RWA initiatives
WOK.US - Ming Yu seeks a share of the drug sector limelight
-
CSPC feels the pain from sweeping cuts in drug prices
1093.HK
-
Precision cancer drugs show promise for Kelun-Biotech
6990.HK
-
So big but so what? Innovent’s license deal fails to excite investors
1801.HK
-
XtalPi scores landmark deal for AI drug discovery
2228.HK
- Hong Kong to welcome world-leading siRNA company as Ribo launches its IPO
